Nortriptyline Hydrochloride Capsule
Product Images NDC 61919-435

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nortriptyline Hydrochloride (NDC 61919-435). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Label 10mg 30)

The text contains information about a medication called Nortriptyline Hydrochloride. It comes in the form of 10mg capsules, with 30 capsules per bottle. The medication is commonly known by its generic name, Pamelor, and each capsule contains Nortriptyline HCL equivalent to 10mg. The rest of the text appears to be product identification codes and numbers and is not useful for understanding the medication.*

FDA Label Image

Image Description (Label 10mg 60)

This appears to be a label of a medication container. The medication is Nortriptyline Hydrochloride, a generic version of Pamelor, and is available in a capsule form with a strength of 10mg, totaling 30 capsules. The medication's NDC number is 053381011, and it has an expiration date of February 2017. The label's lot number is not available.*

FDA Label Image

Image Description (Label25mg60)

This is a product description of Nortriptyline Hydrochloride capsules, a generic equivalent for Pamelor. Each capsule contains 25mg of nortriptyline HCL. The total quantity per container is 60 capsules.*

FDA Label Image

Image Description (Structualformula)

FDA Label Image

Image Description (Table1)

The text describes a table titled "Table 1" that contains information on the effects of drugs compared to placebo on the incidence of suicidality in patients of different age groups. The table shows the age ranges and the drug-placebo difference in the number of cases of suicidality per 1000 patients treated. For patients under 18 years old, there were 14 additional cases compared to placebo, while for patients aged 18-24 there were 5 additional cases. However, for patients aged 25-64, there were fewer cases of suicidality compared to placebo, with 1 fewer case for those aged 25-64 and 6 fewer cases for those aged 65 or older.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.